A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia

This study will evaluate the safety and efficacy of AGN-214868 in patients with postherpetic neuralgia (PHN) - nerve pain.

Inclusion Criteria:

• Persistent postherpetic neuralgia (PHN) with nerve pain present for at least 9 months after onset of herpes zoster skin rash

Exclusion Criteria:

• Female patients with reproductive potential
• Active herpes zoster skin rash
• Current or anticipated treatment with acupuncture, TNS, or steroids
• Current or anticipated use of topical analgesic agents with PHN
• Treatment with botulinum toxin therapy of any serotype within the prior 12 weeks